A Phase 3 interventional study of eculizumab in Paroxysmal Hemoglobinuria, Nocturnal, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 40 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-13.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal — none open to participants now, none under way, none of them phase 3. eculizumab · Hemoglobinuria, Paroxysmal.
Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, this one has the largest enrollment, is one of 2 that started in 2005, is one of 14 in phase 3, and was the 4th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →None of the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal is open now. The open studies under Hemoglobinuria, Paroxysmal, anywhere →
eculizumab: first FDA approval 2007 (SOLIRIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2005.
This study's enrollment of 187 is above the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 37 across the 18 interventional studies. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 18 have an industry lead sponsor. The 8 most frequent:
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca: 3 open now, 7 under way, 2 of them phase 3. Of 26 finished, 18 (69%) have results posted.
Among the 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca, this one is the 3rd largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2005, is one of 12 in phase 3, and was the 3rd registered.
AstraZeneca’s Hemoglobinuria, Paroxysmal studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 35 in Hemoglobinuria, Paroxysmal:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long-term safety of eculizumab in patients with transfusion dependent hemolytic PNH.
An open-label extension study to evaluate long-term safety of eculizumab in PNH patients who had completed the TRIUMPH (C04-001), SHEPHERD (C04-002), and X03-001 studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
600 mg intravenous infusion every week x 4 then 900 mg iv every two weeks
Drug: eculizumab
Also known as: Soliris
Incidence of Treatment-emergent Adverse Events
Time frame: From time of consent to a maximum of 2.5 years of study treatment
Hemolysis as Measured by Change From Baseline in LDH Area Under the Curve
Time frame: From time of first infusion through 24 months of study treatment
Quality of Life as Measured by FACIT-Fatigue Scale Change From Baseline
The FACIT-Fatigue scale is a collection of quality of life questionnaires pertaining to the management of fatigue symptoms due to a chronic illness. The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Patients score each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores range from 0 to 52, with higher score indicating better quality of life.
Time frame: From time of first infusion through 24 months of study treatment
Incidence of Thrombosis After Eculizumab Infusion
Thrombosis was defined as occurrence of major adverse vascular events
Time frame: From time of first ever dose through last dose (up to 24 months of study treatment)
| Milestone | Eculizumab |
|---|---|
| Started | 187 |
| Completed | 176 |
| Not completed | 11 |
| Withdrew: Death | 3 |
| Withdrew: Adverse event | 4 |
| Withdrew: Physician decision | 2 |
| Withdrew: Patient non-compliance | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Participants | Eculizumab |
|---|---|
| Incidence of Treatment-emergent Adverse Events | 182 |
| U/L x Day | Eculizumab |
|---|---|
| Hemolysis as Measured by Change From Baseline in LDH Area Under the Curve | -365185.8 ± 210407.1 |
The FACIT-Fatigue scale is a collection of quality of life questionnaires pertaining to the management of fatigue symptoms due to a chronic illness. The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. Patients score each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores range from 0 to 52, with higher score indicating better quality of life.
| units on a scale | Eculizumab |
|---|---|
| Quality of Life as Measured by FACIT-Fatigue Scale Change From Baseline | 9.24 ± 12.42 |
Thrombosis was defined as occurrence of major adverse vascular events
| Number of events per 100 patient-years | Eculizumab |
|---|---|
| Prior to first eculizumab dose | 7.82 |
| From first dose of eculizumab through last dose | 1.99 |
Collected over From time of consent to a maximum of 2.5 years of study treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eculizumab | 3/187 (1.6%) | 57/187 (30.5%) | 180/187 (96.3%) |
| Event | Eculizumab |
|---|---|
| HaemolysisBlood and lymphatic system disorders | 5/187 |
| Abdominal painGastrointestinal disorders | 5/187 |
| PyrexiaGeneral disorders | 5/187 |
| Paroxysmal Nocturnal HaemoglobinuriaRenal and urinary disorders | 4/187 |
| AnaemiaBlood and lymphatic system disorders | 3/187 |
| CholecystitisHepatobiliary disorders | 3/187 |
| Viral InfectionInfections and infestations | 3/187 |
| Aplastic anaemiaBlood and lymphatic system disorders | 2/187 |
| CholelithiasisHepatobiliary disorders | 2/187 |
| Portal vein thrombosisHepatobiliary disorders | 2/187 |
| Event | Eculizumab |
|---|---|
| NasopharyngitisInfections and infestations | 74/187 |
| HeadacheNervous system disorders | 61/187 |
| Upper Respiratory Tract InfectionInfections and infestations | 58/187 |
| DiarrhoeaGastrointestinal disorders | 44/187 |
| NauseaGastrointestinal disorders | 39/187 |
| VomitingGastrointestinal disorders | 38/187 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 33/187 |
| Back PainMusculoskeletal and connective tissue disorders | 32/187 |
| Influenza like IllnessGeneral disorders | 29/187 |
| CoughRespiratory, thoracic and mediastinal disorders | 29/187 |
| Age, Continuous(years) | Eculizumab |
|---|---|
| Mean | 42.1 ± 14.1 |
| Sex: Female, Male(Participants) | Eculizumab |
|---|---|
| Female | 101 |
| Male | 86 |
| Race/Ethnicity, Customized(Participants) | Eculizumab |
|---|---|
| Asian | 6 |
| Black | 7 |
| Caucasian | 168 |
| Other | 6 |
Plan to share: No
Ran from May 2005 to primary completion in Sep 2008, 40 months.
Results were first posted in Jun 2017, 8 years 9 months after primary completion.
Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's 40 months is above that.
Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eculizumab
Alexion Pharmaceuticals, Inc. →